The Jon & Marc Podcast
Key Takeaways * Two New MDLs Established: The JPML has officially formed two new mass tort dockets: the Dupixent litigation in the District of New Jersey and the Spinal Cord Stimulator litigation against Boston Scientific in the Central District of California. * Dupixent Injury Focus: The Dupixent MDL targets a rare T-cell subtype of non-Hodgkin lymphoma , drawing from a massive potential pool of roughly 800,000 users and projected to eventually encompass a few thousand cases. * Spinal Cord Stimulator Scope Limited: Plaintiffs requested an industry-wide spinal cord stimulator MDL, but the JPML limited the initial consolidation to Boston Scientific due to distinct discovery tracks and trade secret concerns. An Abbott Laboratories MDL may follow later this year or early next year. * J&J Clinches Talc Victory: Johnson & Johnson secured a surprising 10-2 defense verdict in the second California state court talc bellwether trial. The outcome came down to a battle of the experts, where jurors expressed skepticism over plaintiff experts who failed to warn their own patients of the risks. * Paraquat Settlement Disruption: In the Paraquat MDL, the judge ordered a mandatory 10% case-specific workup and depositions for three law firms whose clients overwhelmingly opted out of a recent settlement proposal. Concurrently, Philadelphia state court cases are facing renewed jurisdiction challenges ahead of late-summer trials.
83 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de The Jon & Marc Podcast!